Cephalon, Inc.
9
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
77.8%
7 terminated/withdrawn out of 9 trials
22.2%
-64.3% vs industry average
44%
4 trials in Phase 3/4
350%
7 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Cyclobenzaprine Extended Release (ER) for Fibromyalgia
Role: collaborator
Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer
Role: lead
The Nuvigil and Provigil Pregnancy Registry
Role: lead
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Role: collaborator
A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus
Role: lead
A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)
Role: lead
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Role: collaborator
Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
Role: lead
Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
Role: lead
All 9 trials loaded